Global Incretin Based Drugs Market (2023 Edition)

Global Incretin Based Drugs Market (2023 Edition): Analysis By Drug Type (Glucagon-like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors), Route of Administration, By Indication, By Region, By Country: Market Insights and Forecast (2019-2029)

Executive Summary

Azoth Analytics has released a research report titled “Incretin Based Drugs Market (2023 Edition)” which provides a complete analysis of the global Incretin Based Drugs industry in terms of market segmentation By Drug Type (Glucagon-like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors), By Route of Administration (Oral, Injectables) and By Indication (Diabetes, Obesity) for the historical period of 2018-2022, the estimated year of 2023 and the forecast period of 2024-2028.

The research report covers a detailed analysis of the regions (Americas, Europe, APAC, Middle East Africa) and 10 countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast. The research also assesses growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market's evolution.

During the forecast period, 2024-2029, the Global Incretin Based Drugs market is expected to grow at a CAGR of 6.8%. The Global Incretin Based Drugs Market is expected to generate USD 64.28 billion by the end of 2029, up from USD 40.72 Billion in 2022.

Incretin-based drugs are the first-of-its-kind anti-hyperglycemic medications that have been developed by specifically targeting a recognized pathophysiological abnormality in type 2 diabetes. The global increase in the prevalence of type 2 diabetes has a significant impact on the demand for incretin-based drugs. The growing incidence of diabetes can be attributed to various factors, including sedentary lifestyles, poor dietary habits, and the ageing demographic.

In comparison to many other anti-hyperglycemic medications, incretin-based drugs offer some notable benefits, including the lack of an elevated risk of hypoglycemia or weight gain. The DPP4Is and GLP-1RAs exhibit unique efficacy and tolerability profiles, providing physicians with the opportunity to choose the most suitable medication for each patient, taking into account factors such as disease status (as indicated by HbA1c percentage), body weight, and patient preference for self-administered injectable drugs. The demand for Incretin-based drugs is expected to grow exponentially as the blockbuster drugs in the market become accessible in generic form and as upgraded formulations with reduced dosing frequency are introduced.

Scope of the Report

• The report analyses the Incretin Based Drugs Market by Value (USD Billion).
• The report presents the analysis of Incretin Based Drugs Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
• The report analyses the Incretin-Based Drugs Market by Drug Type (Glucagon-like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors).
• The report analyses the Incretin Based Drugs Market by Route of Administration (Oral, Injectables)
• The report analyses the Incretin-Based Drugs Market by Indication (Diabetes, Obesity).
• The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Drug Type, By Route of Administration and by Indications.
• Also, the major opportunities, trends, drivers, and challenges of the industry have been analyzed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk, AstraZeneca PLC, Merck & Co., Inc., Pfizer, Novartis AG, Takeda Pharmaceuticals, Bristol Myers Squibb, Structure Therapeutics.